NCT02305329View on ClinicalTrials.gov

Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions

Epilepsy

Interventions

DRUG

BIA 9-1067

All Listed Sponsors

lead

Bial - Portela C S.A.

INDUSTRY

NCT02305329 - Dosage Form Proportionality of Opicapone To-Be-Marketed Formulation | Biotech Hunter | Biotech Hunter